 |
 |

Evaluating Pharmacogenetic Tests
A Case Example
Carol L. Freund, PhD;
David F. Gregory, PharmD;
Ellen Wright Clayton, MD, JD
Arch Pediatr Adolesc Med. 2004;158:276-279.
Work in human genetics is revealing genes that affect the safe and effective use of pharmaceuticals. Primary care physicians are already receiving advertisements for tests for these variations that emphasize the value of learning about their patients' susceptibility to adverse reactions in order to avoid them. We propose a strategy for the critical evaluation of such offers to ensure the optimal use of these tests.
From the Department of Pediatrics (Drs Freund, Gregory, and Wright Clayton), the Center for Genetics and Health Policy (Drs Freund and Wright Clayton), and the School of Law (Dr Wright Clayton), Vanderbilt University, Nashville, Tenn.
|